Innate Pharma Stock Investor Sentiment
| IPHA Stock | USD 2.00 0.01 0.50% |
About 62% of Innate Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Innate Pharma suggests that many traders are alarmed. The current market sentiment, together with Innate Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Innate Pharma stock news signals to limit their universe of possible portfolio assets.
Innate |
Innate Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Innate Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Innate Pharma that are available to investors today. That information is available publicly through Innate media outlets and privately through word of mouth or via Innate internal channels. However, regardless of the origin, that massive amount of Innate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Innate Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Innate Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Innate Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Innate Pharma alpha.
Innate Pharma Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024 | 01/16/2025 |
2 | Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York | 01/21/2025 |
3 | Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors | 01/27/2025 |
4 | HC Wainwright Reiterates Buy Rating for Innate Pharma - MarketBeat | 02/10/2025 |
5 | Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference | 02/27/2025 |
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |